Redcare Pharmacy: 108% Rx Sales Surge in Sept; Boosts Q4 Marketing Plans

• Redcare Pharmacy achieved 81% growth in Q3 Rx sales in Germany, with a 108% increase in September.
• The company plans to accelerate marketing in Q4 due to strong e-Rx metrics, focusing on repeat order rate and average basket size.
• Full-year guidance for 2024 has been updated, with total group sales expected to be EUR 2.35 to EUR 2.5 billion.
• Non-Rx sales growth is projected at 20-25%, up from the previous 15-25% forecast.
• MediService sales are expected to grow in the lower half of single digits, revised from mid-single digits.
• The adjusted EBITDA margin is now forecasted at 1.2-2.2%, down from the previous 2-4% estimate.

The next important date, Quarterly report, at Redcare Pharmacy is on 29.10.2024.

The price of Redcare Pharmacy at the time of the news was 136,75EUR and was up +1,22 % compared with the previous day.
14 minutes after the article was published, the price was 141,00EUR this corresponds to a plus of +3,11 % since publication.
At this time, the index MDAX was at 26.573,60PKT (-0,78 %).

Redcare Pharmacy

-0,08 %

-3,57 %

+3,40 %

-7,46 %

-18,04 %

+46,52 %

+104,29 %

+311,00 %

ISIN:NL0012044747WKN:A2AR94

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• Max